文献速递骨质疏松与代谢性骨病创伤骨科

急性期反应对住院老年骨质疏松性骨折患者唑来膦酸治疗后死亡率和再骨折的影响

The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients.
PubMed 文献 · Osteoporos Int · 2023-05-29

该研究纳入674例接受骨科手术的老年骨质疏松性骨折患者,探讨首次唑来膦酸输注后急性期反应(APR)与长期死亡和再骨折的关联。发生APR者死亡风险较未发生者高97%,再骨折风险较未发生者低73%。

要点

  • APR+患者全因死亡风险显著高于APR-患者,HR 1.97(95%CI 1.09-3.56;P=0.02)。
  • APR+患者再骨折风险显著低于APR-患者,亚分布HR 0.27(95%CI 0.11-0.70;P=0.007)。
  • 首次唑来膦酸输注后发生APR与死亡风险升高存在潜在关联。

核心结论

  • 研究提示APR的发生与死亡风险升高存在潜在关联。
  • 骨科手术后首次剂量唑来膦酸对老年骨质疏松性骨折患者具有预防再骨折的保护作用。

研究设计与样本

  • 回顾性观察研究,基于中国一家三级甲等医院骨质疏松性骨折登记系统前瞻性收集的数据库。
  • 最终分析纳入674例50岁及以上、新发髋部或形态学椎体骨质疏松性骨折、骨科手术后首次接受唑来膦酸治疗的患者。
  • APR定义为唑来膦酸输注后前3天最高腋温大于37.3°C。
  • 采用多因素Cox比例风险模型比较APR+与APR-患者全因死亡风险,采用竞争风险回归分析在校正死亡后检验APR与再骨折的关联。

主要发现

  • 完全校正Cox比例风险模型中,APR+患者死亡风险显著高于APR-患者,HR 1.97(95%CI 1.09-3.56;P=0.02)。
  • 校正竞争风险回归分析中,APR+患者再骨折风险显著低于APR-患者,亚分布HR 0.27(95%CI 0.11-0.70;P=0.007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study involving 674 elderly osteoporotic fracture (OPF) patients undergoing orthopedic surgery investigated the long-term outcomes of acute phase reaction (APR) after initial zoledronic acid (ZOL). Those who had an APR had a 97% higher risk of mortality and a 73% lower rate of re-fracture than patients who did not. INTRODUCTION: Annual infusion of ZOL efficiently decreases the risk of fracture. A temporary APR, consisting of flu-like symptoms, myalgia, and fever, is frequently observed within 3 days after the first dose. This work aimed to identify whether the occurrence of APR after initial ZOL infusion is a reliable indicator of drug efficacy for mortality and re-fracture in elderly OPF patients undergoing orthopedic surgery. METHODS: This retrospectively observed work was constructed on a database prospectively collected from the Osteoporotic Fracture Registry System of a tertiary level A hospital in China. Six hundred seventy-four patients 50 years old or older with newly identified hip/morphological vertebral OPF who received ZOL for the first time after orthopedic surgery were included in the final analysis. APR was identified as a maximum axillary body temperature greater than 37.3 °C for the first 3 days after ZOL infusion. We utilized models of multivariate Cox proportional hazards to compare the risk of all-cause mortality in OPF patients with APR (APR+) and without APR (APR-). Competing risks regression analysis was used to examine the association between the occurrence of APR and re-fracture when mortality was taken into account. RESULTS: In a fully adjusted Cox proportional hazards model, APR+ patients had a significantly higher risk of death than APR- patients with a hazard ratio [HR] 1.97 (95% CI, 1.09-3.56; P-value = 0.02). Furthermore, in an adjusted competing risk regression analysis, APR+ patients had a significantly reduced risk of re-fracture compared with APR- patients with a sub-distribution HR, 0.27 (95% CI, 0.11-0.70; P-value = 0.007). CONCLUSIONS: Our findings suggested a potential association between the occurrence of APR and increased mortality risk. An initial dose of ZOL following orthopedic surgery was found to be protective against re-fracture in older patients with OPFs.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Lu K, Wu YM, Shi Q, et al. The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients. Osteoporos Int. 2023. PMID: 37247006. doi:10.1007/s00198-023-06803-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。